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ABSTRACT
INTRODUCTION: Cardiovascular diseases are one of the leading 
causes of mortality worldwide. It is known to have a reduced 
incidence in premenopausal women compared to the opposite 
sex. This appears to be related to the female hormones and their 
fluctuation throughout the menstrual cycle.
Objectives: To evaluate and correlate behavior patterns of cerebral 
dynamics and arterial reactivity throughout the menstrual cycle and to 
identify possible differences caused by the use of oral contraceptives 
(OC).
METHODS: The sample consisted of 21 healthy, eumenorrheic 
and non-smoking young womens, belonging to the 18-21 age 
group. There were two distinct groups: 11 in the group without oral 
contraceptive (SCO) and 10 in the oral contraceptive group (CCO). 
Both groups performed an evaluation in the menstrual phase (MP), 
from the 1st to the 4th day, and in the ovulatory phase (OP), from 
the 12th to the 16th day. The third evaluation was performed in the 
late luteal phase (LLP) from the 26th to the 30th day, in the SCO 
group and in the OC pause, from the 21st to the 28th day, in the CCO 
group. Four noninvasive procedures were performed: blood pressure 
measurement, axillary temperature, carotid and right brachial artery 
sonography.
RESULTS: There were no statistically significant differences in 
carotid parameters, however, there were variations in the velocity 
of the systolic peak (VPS) of the common carotid artery (CCA) 
and internal carotid artery (ICA) and the ICA resistance index (IR), 
throughout the cycle. The SCO group showed a significant increase 
in FMD from MF to OF (p = 0.023), decreasing in LL (p = 0.012). 
The CCO group demonstrated a relative stabilization of FMD values. 
In OP, there were statistically significant differences between the two 
groups in relation to the FMD value (p = 0.040).
CONCLUSIONS: Cyclic fluctuations of estrogen appear to 
influence cerebral vascular impedance and arterial reactivity but 
in different proportions. In conclusion, this study supports the idea 
of standardizing the timing of vascular testing in a premenopausal 
woman.
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INTRODUCTION
Estrogen and progesterone (PG) are the main hormones involved in 
the development, maintenance and control of women’s reproductive 
function. It produces several types of estrogen, being estradiol 
(17β-estradiol or E2) the most important in terms of regulation of the 
menstrual cycle, produced mainly by the ovaries[1].
    Cardiovascular diseases (CVDs) are responsible for more than 
40% of mortality in developed countries[2]. Premenopausal women 
benefit from a lower incidence of CVDs when compared with men 
of the same age; proportionality reached after menopause or even 
at higher risk[3,4]. This premise fits the role of estrogen, also present 
in men but at lower levels. The “cardioprotective” effect of E2 and 
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necessitating the presence of two cofactors, oxygen and phosphate 
dinucleotide adenine nicotinamide (NADPH)[13]. This mechanism is 
correctly functioning in the arteries with a normal endothelium, being 
abolished in cases of endothelial dysfunction.
    The NO is known to be a potent vasodilator, inhibitor of platelet 
aggregation and adhesion and proliferation of smooth muscle 
cells[4,6,12]. In fact, in response to an increase in E2 concentration 
throughout the menstrual cycle, an increase in the bioavailability of 
NO will occur and due to its vasodilatory functions a direct action 
on the arterial wall physiology is predicted, mirror with hormonal 
fluctuation, which may play a role in the pathophysiology of 
cardiovascular risk in women[14].
    As in the peripheral circulation, E2 receptors are located in the 
cerebral vasculature, regulating cerebral vascular tone through 
the modulation of cellular functions. Also here, E2 facilitates the 
production of vasoactive substances derived from the endothelium, 
such as NO and others. E2 is classically known for its neuroactive 
properties[15]. The vasodilatory effect of estrogen in cerebral vessels 
has been confirmed in women with hormone replacement therapy 
(HRT), however, their influence on cerebral blood flow in humans is 
still uncertain[16,17]. As the concentration of E2 varies throughout the 
menstrual cycle, it may be expected that the flow conditions within 
the brain will be modified accordingly[18].
Hormonal contraceptives (HC)
There are several existing HC products that base their action on 
women’s endocrine physiology. Oral contraceptive pill (OCP) is the 
most used method in the USA[19] not only for pregnancy prevention but 
also for therapeutic purposes. Its formula is based on the use of two 
synthetic hormones that mimic estrogen and progesterone endogenous, 
namely the ethinylestradiol (EE) and progestagens[19,20]. The OCP can 
be constituted by progestogen alone or the combination of estrogen 
and progesterone synthetics (combined OCP). These last are the most 
used in adolescence, based on the daily intake of 21 pills with single-
phase, biphasic or three-phase formulations, followed by a pause of 
7 days or intake of 7 inert pills[20]. The dosage of EE varies can be of 
high dose (≥ 50 mcg) or low dose (< 50 mcg)[19]. Its action is based 
on the inhibition of pulsatile secretion of GnRH, which consequently 
suppresses FSH and LH levels, avoiding follicular development and 
ovulation[21,22], leading to low and stable levels of E2.
    Following the increasing use of these methods, the side effects 
began to emerge. Knowing that the E2 influences the cardiovascular 
system, a change in their concentrations by HC will have an 
influence on this system. Women who use HC have a higher risk for 
cardiovascular system disorders such as acute myocardial infarction, 
stroke, venous thromboembolism, pulmonary embolism and 
hypertension[14,20]. Although these side effects were reduced with the 
low dose OCP insertion, they were not eliminated.
Objective
This research has as objective to evaluate the behavior of carotid 
arteries and endothelial function throughout the menstrual cycle in 
healthy young female users and non-users of oral contraceptive (OC) 
and, thus, to identify different patterns of behavior.
METHODS
Population
The sample consisted of 21 young, clinically healthy, nulliparous 
and of reproductive-age, belonging to the 18-21 age group, all of 
them students from the Clinical Physiology Degree at the Coimbra 
its role in CVDs is associated with the effect on vasculature, lipid 
metabolism and blood pressure (BP)[1,2,3,4].
Endocrine physiology of women
The popular term “period” refers to menstruation that all healthy 
women experience monthly. In scientific terms it corresponds to 
a physiological and cyclic desquamation of the woman’s uterine 
wall in response to a set of hormonal and nervous interactions5. The 
term eumenorreic is used to define a normal and regular menstrual 
cycle. This means a menstrual blood flow of approximately 30 ml, 
not to exceed 80 ml, and whose duration varies from 4 to 6 days[5]. 
It is generally accepted that a normal duration of a menstrual cycle 
corresponds to the period between the first day of menstruation 
in a given cycle to the beginning of the next menstrual cycle, 
being approximately 28 days (acceptable variation of 25-30 days)
[5]. Although there are different divisions of the menstrual cycle, 
the most general and accepted one is the separation into two main 
phases: follicular/preovulatory/proliferative phase and luteal/post-
ovulatory/secretory phase[2,5]. Endocrine control during these phases 
is supported by positive and negative feedback mechanisms based 
complex hypothalamic, pituitary, ovarian (hypothalamic-pituitary-
ovarian axis) interactions and uterine interactions[2,3].
    In the absence of pregnancy E2 and PG levels are minimal, 
resulting in desquamation of the endometrium resulting in 
menstruation. Initially, an increase in follicle-stimulating hormone 
(FSH) is observed, a consequence of a pulsatile secretion of 
gonadotrophin releasing hormone (GnRH) by the hypothalamus. The 
increase in FSH will result in a recruitment of primordial follicles 
in which only one will follow for ovulation - dominant follicle. 
Around the 14th day of the cycle, the pre-ovulatory follicle produces 
an abrupt E2 that leads to an outbreak of FSH and luteinizing 
hormone (LH). These hormonal peaks cause a follicle maturation 
and consequent ovulation, starting a luteal phase with a duration of 
approximately 14 days. The follicle that released the ovule happens 
to be called corpus luteum/yellow body, responsible for the secretion 
of PG. If the ovule is not fertilized, the corpus luteum degenerates 
and decreases concentrations of E2 and PG, starting a new cycle[2,5].
Relationship between E2 e nitric oxide (NO)
The E2 presents several types of specific receptors (estrogen 
receptors, ER), distributed in both sexes by the various systems, 
with gene expression being different according to their location in 
the target cells. Two classical subtypes of receptors are known: ERα, 
more abundant, and ERβ[4,6]. In recent years a growing interest in this 
subject has led to a better understanding of the interaction between 
E2 and their receptors, their locations and other possible ligands. The 
modulatory action of E2 is made on the basis of genomic mechanisms 
(slow) and non-genomic mechanisms (fast)[7]. Through studies in 
animal and human models, McNeil et al[8] 1999, Stironeet et al[9] 
2003 and Russel et al[10] 2000 tried to demonstrate the physiological 
functioning of these mechanisms. The hormone-receptor complex 
acts as a transcription cofactor in the genomic mechanism, by 
binding to specific regions of the DNA, occurring the regulation of 
gene expression, being a slow process[6,11]. On the other hand, the 
non-genomic mechanism is based on the interaction of E2 with the 
receptor bound to the plasma membrane of the target cell that rapidly 
activate intracellular signaling through second messengers[6,7]. 
    In the vascular system, the main endogenous source of NO is 
a nitric oxide synthaseable endothelial enzyme (eNOS or NOS3)
[12]. When activated, it stimulates the biosynthesis of NO in the 
endothelial cells, having as substrate the amino acid L-arginine 
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sites in the arteries were standardized and fixed in order to avoid 
further variations, according to the articles found[18,23]: starting at the 
common carotid artery (CCA), the sample volume was placed 1-2 
cm below the bifurcation, followed by the carotid artery (ECA) and 
internal carotid artery (ICA), with reference to 1-1.5 cm and 1.5-2 
cm distal to the bifurcation, respectively. For analysis, information 
on the intima-media thickness (IMT) of CCA, systolic and diastolic 
diameter, systolic peak velocity (VPS) and endodiastolic velocity 
(VED) of CCA, ICA and ECA were collected. The mean velocity was 
then calculated according to the equation (VPS + 2*VED) /3 for each 
of the arteries. The resistance index (RI) and the pulsatility index (PI) 
were calculated based on the currently accepted formulas[24,25].
    Finally, the ultrasound study of the upper limb was followed, 
where all evaluations were performed on the right arm. With a slight 
abduction of the arm, a mark 3-5 cm above the antecubital fossa 
was made, in order to guarantee the fixation of the evaluation site. 
To facilitate the location of the artery, color flow mapping and basal 
diastolic diameter of the brachial artery (DBAB) were used, with 
reference to the R wave peak of the electrocardiogram. The distance 
between the proximal and distal limits of the intima was measured. 
Once the basal diameter was obtained, the armband previously 
placed distally at the measurement site was inflated for 5 minutes 
at suprasystolic pressure. After 60 seconds of rapid deflation of the 
armband, the post hyperaemic diastolic diameter of the brachial 
artery (DPHAB) was measured - Figure 1. All measurements were 
taken 3 times at the same reference point and the mean was recorded 
as the final value. After that, flow-mediated dilation (FMD) was 
calculated based on the formula (DPHAB-DBAB)/DBAB*100[26].
Statistical Analysis
The data obtained was transferred and grouped in a database built in 
the program Excel 2013 (Microsoft Office, Redmond, WA) and then 
imported and statistically analyzed in the program SPSS Statistics 
version 25 for Windows (IBM, Armonk, NY).
    The Shapiro-Wilks test was used to confirm the distribution of 
continuous variables. These were checked for variance homogeneity 
using the Levene test. Simple descriptive statistics were used for the 
general characterization of the population and the distribution of the 
variables. Continuous variables were presented as mean ± standard 
deviation (SD) and as absolute frequency (percentage) for qualitative 
variables. The ANOVA test was used for repeated samples to evaluate 
the behavior of the continuous variables in the different phases of the 
menstrual cycle, both in the total sample and in the groups constituted 
for the analysis. The Greenhouse-Geisser correction was applied 
whenever sphericity was violated, and the Bonferroni adjustment for 
degrees of freedom was used in multiple comparisons to locate the 
significant effects of a factor. The Student’s t-test for independent 
samples was used for the comparisons of continuous variables 
between groups, during the 3 evaluation phases. Qualitative variables 
were compared using the chi-square test (χ2) and Fisher’s exact test, 
as appropriate.
    The statistical significance (p) criterion used was a value of p ≤ 
0.05 for a confidence interval of 95%.
RESULTS
Descriptive Analysis
Twenty-two young women were recruited with an average 
age of 19.81 ± 0.87. From this initial sample, a young woman 
belonging to the CCO group was excluded because she presented 
hypercholesterolemia from the age of 6 years and unknown mild 
Health School. Participants were recruited through the disclosure of 
the study by the researchers themselves. The selection criteria were 
defined based on previously analyzed articles[18,24] and verified based 
on a questionnaire addressed to the participants, which excluded 
all those with antecedents that could influence the results. So, only 
nulliparous, considered healthy girls, with regular menstrual cycles 
in the last 6 months and menarche for at least 4 years were included. 
To avoid HC variability, only the young people whose contraceptive 
was the oral contraceptive pill were included. Exclusion criteria were 
alcohol abuse, smoking, diabetes, head trauma, cardiovascular and 
gynecological problems, current or previous pregnancy, irregular 
menstrual cycles, use of medication during the sample collection and 
in the last 3 months. As a fundamental requirement, young women 
with oral contraceptives (OC) did not interrupt their intake during the 
evaluation period.
Study Design
They were divided into two groups: a group of 10 young people 
using oral contraceptive (CCO) and a group of 11 young people who 
did not use a hormonal contraceptive (SCO). As they all had regular 
menstrual cycles, the length of the menstrual cycle was standardized 
for a period of 28 days, starting on the first day of menstruation. 
The stipulation and marking of the evaluations was based on the 
menstrual calendar and accordingly to the hourly availability of the 
participants. Thus, before the start of the collection, with the help of 
the researchers, the young women made a forecast of the evaluation 
phases. These were subject to 3 moments of evaluation corresponding 
to 3 phases of the menstrual cycle that differentiated between the 2 
groups. Both groups performed an evaluation in the menstrual phase 
(MP), from the 1st to the 4th day, and in the ovulatory phase (OP), 
from the 12th to the 16th day. The third evaluation was performed in 
the late luteal phase (LLP), from the 26th to the 30th day, in the SCO 
group and from the 21st to the 28th day, in the CCO group, in the 
pause of the contraceptive pill.
    Each participant was informed of all the essential information 
about the study and guaranteed the confidentiality of the data 
obtained in order to sign free and informed consent to enable their 
participation in the study.
Procedure
Each young woman was asked not to perform vigorous exercise 
and not drink alcohol and caffeine at least 12 hours before each test. 
All the young women rested for a period of 5-10 minutes in dorsal 
decubitus position. The laboratory was low lit, silent and temperature 
controlled (22º / 23ºC). In order to avoid inter-observer errors all 
exams were performed by the same investigator who was not aware 
of the phase of the menstrual cycle. 
    We started the collection with the measurement of the BP by a 
certified measuring device, Riester ® model Ri-Champion N. In the 
first evaluation the BP was measured in both arms and if there were 
no significant differences, the remaining evaluations were always 
performed on the left arm and the mean value of three measurements 
of systolic blood pressure (SBP), diastolic blood pressure (DBP) 
and heart rate (HR) was recorded. At the same time, the axillary 
temperature was measured in all evaluations using a digital 
thermometer, Ri-gital ®.
    After ECG monitoring, we started the carotid evaluation using 
a GE ® Vivid T8 / Vivid T8 Pro ultrasound. A linear L6-12 probe 
was used at a frequency of 6-13 MHz. In the first evaluation, it was 
performed bilaterally and if no significant differences were verified, 
the left side was used in the remaining evaluations. The measurement 
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Figure 2 Evolution of flow-mediated dilation of the right brachial artert troughout the menstrual cycle.
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Figure 1 Two-dimensional image of the right brachial artery.
arterial hypertension. So, 21 healthy young women with regular 
menstrual cycles of 28 days were included, considering the possible 
variation up to 2 days. Table 1 shows the mean values ± SD of the 
anthropometric and hemodynamic data that characterize the sample.
    The total sample is characterized by a body mass index (BMI) 
of 21.33 ± 1.87 kg /m² in which only one young woman belonging 
to the CCO group was overweight. All participants had a menarche 
age for at least 4 years. None of the participants were on prolonged 
consumption of relevant medication. All the young members in 
the contraceptive group took combined monophasic OCs for at 
least 1 year. None of the participants were smokers or had any 
relevant disease. In terms of cardiovascular antecedents (CVAs) of 
direct parents: 12 answered affirmatively (7 SCO and 5 CCO) and 
42% reported hypertension, 33% AMI, 8% diabetes, 42% stroke, 
8% hypercholesterolemia. Most were not regular users of soft 
drinks (90.5%) and more than half do not attend any type of sport 
regularly (66.7%), standing out a former federate in non-practicing 
swimming since the age of 14. About 81% of participants say they 
consume alcohol but on an infrequent scale. In relation to caffeine 
consumption, 38.1% reported consuming 2 cups of coffee a day. The 
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hemodynamic data of the total sample are within normal values and 
there were no significant differences between the two groups under 
study.
Evolutionary analysis of the total sample
No statistically significant differences were found in any of the 
parameters of the total sample over the 3 evaluation phases in the 
same participant. The respective mean values ± SD of the variables 
evaluated are presented in Table 2. The SBP and DBP were lower 
in LLP. The VPS value of the CCA has the lowest value in the OP, 
reaching the maximum value in the LLP. Similar to CCA behavior, 
VPS value of the ICA reached its lowest value in OP, increasing to 
its maximum value in LLP. Although not statistically significant, the 
FMD (p = 0.186) increases from MP to OP, decreasing in LLP to 
values close to baseline.
Intra-group evolutionary analysis
Table 3 shows the results on the SBP, DBP, HR, temperature, carotid 
Table 1 Anthropometric and hemodynamic characterization of the 
sample.
Parameters Total (n = 21) Group SCO (n = 11)
Group CCO 
(n = 10)
p (c/OC 
vs. s/OC)
Age, years 19.81 ± 0,87 19.91 ± 0.94 19.70 ± 0.82 0.597
Weight, kg 58.71 ± 6.06 58.36 ± 4.55 59.10 ± 7.64 0.789
Height, m 1.66 ±  0.06 1.66 ± 0.05 1.66 ± 0.07 0.889
BMI, kg/m² 21.33 ± 1.87 21.17 ± 1.54 21.51 ± 2.24 0.691
Menarche, anos 12.29 ± 1.23 12.09 ± 0.83 12.50 ± 1.58 0.461
CVs antecendent 0.670
Yes, % (n)                     42.9% (9) 64.6% (7) 50.0% (5) 
No, % (n) 57.1% (12) 36.4% (4)  50.0% (5)
SBP, mmHg 115.10 ± 8.33 115.68 ± 7.95 114.47 ± 9.12 0.748
DBP, mmHg 68.492 ± 5.35 69.21 ± 4.84 67.70 ± 6.02 0.531
HR, bpm 72.05 ± 10.30 71.36 ± 9.62 72.80 ± 11.48 0.758
Temperature, C° 36.11 ± 0.61 36.07 ± 0.72 36.16 ± 0.48 0.751
IMT, mm 0.429 ± 0.046 0.436 ± 0.051 0.420 ± 0.042 0.433
Table 2 Global evolution of the parameters of the total sample, along the 
menstrual cycle.
Parameters MP (1º-4º dia) OP (12º-16º dia) LLP (26º-30º dia) p
SBP, mmHg 115.103 ± 8.330 113.762 ± 8.726 113.016 ± 8.529 0.384
DBP, mmHg 68.492 ± 5.348 67.794 ± 6,218 66.937 ± 6.358 0.344
HR, bpm 72.05 ± 10.298 70.857  ± 7.786 75.857 ± 9.329 0.097
Temperature, C° 36.114 ± 0.606 36.286 ± 0.408 36.362 ± 0.591 0.094
IMT, mm 0.429 ± 0.046 0.429 ± 0.046 0.448 ± 0.068 0.353
CCA VPS, cm/s 103.494 ± 19.613 101.754 ±15.713 108.300 ± 15.883 0.220
CCA VED, cm/s 22.773 ± 5.455 20.136 ± 5.040 21.687 ± 4.373 0.111
CCA PI 1,623 ± 0.242 1.729 ± 0.243 1.709 ± 0.233 0.107
CCA RI 0.775 ± 0.058 0.799 ± 0.053 0.796 ± 0.047 0.080
ICA VPS, cm/s 90.693 ± 19.143 88.336 ± 17.466 96.849 ± 19.703 0.073
ICA VED, cm/s 29.178 ± 7.761 26.247 ± 5.409 28.054 ± 4.986 0.223
ICA PI 1.247 ± 0.256 1.308 ± 0.334 1.342 ± 0.178 0.390
ICA RI 0.674 ± 0.074 0.686 ± 0.121 0.705 ±  0.051 0.417
ECA VPS, cm/s 70.764 ± 13.074 67.339 ±  15.034 68.294 ±  15.003 0.599
ECA VED, cm/s 7.649 ± 7.695 6.219 ± 3.313 6.664 ± 4.119 0.612
ECA PI 2.270 ± 0.419 2.290 ± 0.388 2.275 ± 0.344 0.972
ECA RI 0.894 ± 0.090 0.900 ± 0.067 0.899 ± 0.055 0.937
FMD, % 11.691 ± 5.135 13.728 ± 4.734 11.504 ± 2.882 0.186
FMD absolute, 
mm 0.321 ± 0.127 0.381 ± 0.125 0.324 ± 0.080 0.152
Table 3 Evolution of variables along the menstrual cycle, in the group 
without oral contraception.
Parameters MP (1º-4º day) OP (12º-16º day) Pause OC (21º-28º day) p
SBP, mmHg 114.467 ± 9.118 113.433 ± 9.402 110.00 ± 7.362 0.209
DBP, mmHg 67.700 ± 6.019 67.733 ± 6.629 65.400 ± 5.887 0.288
HR, bpm 72.80 ± 11.478 68.00 ± 5.716 74.100 ± 8.504 0.264
Temperature, C° 36.160  ± 0.479 36.400 ± 0.362 36.520 ± 0.270 0.078
CCA VPS, cm/s 102.910 ± 20.037 102.534 ± 18.702 105.618 ± 16.965 0.818
CCA VED, cm/s 23.822 ± 5.315 20.288 ± 4.936 21.980 ± 3.242 0.079
CCA PI 1.576 ± 0.203 1.724 ± 0.238 1.672 ± 0.136 0.065
CCA RI 0.765  ± 0.053 0.799 ± 0.052 0.790 ± 0.030 0.070
ICA VPS, cm/s 90.199 ± 20.373 89.930 ± 16.041 96.196 ± 15.210 0.442
ICA VED, cm/s 28.304 ± 7.073 24.531 ± 4.514 27.484 ± 4.693 0.389
ICA PI 1.268 ± 0.331 1.403 ± 0.278 1.362 ± 0.190 0.415
ICA RI 0.677 ± 0.96 0.719 ± 0.074 0.711 ± 0.054 0.293
ECA VPS, cm/s 74.197 ± 9.321 66.518 ± 12.467 63.076 ± 17.065 0.110
ECA VED, cm/s 9.374 ± 10.994 5.032 ± 3.237 5.553 ± 3.060 0.229
ECA PI 2.236 ± 0.582 2.414 ± 0.361 2.296 ± 0.371 0.463
ECA RI 0.880 ± 0.128 0.921 ± 0.051 0.902 ± 0.055 0.437
FMD, % 12.679 ± 7.067 11.546 ± 4.176 12.401 ± 3.199 0.863
FMD absolute, 
mm 0.340 ± 0.171 0.320 ± 0.114 0.340 ± 0.084 0.914
Table 4 Evolution of the parameters of the group with oral contraception, 
along the menstrual cycle.
Parameters MP (1º-4º day) OP (12º-16º day)
LLP (26º-30º 
day) p
SBP, mmHg 115.682 ± 7.950 114.061 ± 8.515 115.758 ± 8.908 0.521
DBP, mmHg 69.212 ± 4.836 67.848 ± 6.145 68.333 ± 6.720 0.519
HR, bpm 71.36  ± 9.615 72.545 ± 9.234 77.455 ± 10.153 0.207
Temperature, C° 36.073 ± 0.724 36.182 ± 0.436 36.218 ± 0.765 0.680
CCA VPS, cm/s 104.025 ± 20.184 101.045 ± 13.336 110.737 ± 15.224 0.238
CCA VED, cm/s 21,820 ± 5.655 19.997 ± 5.370 21.420 ± 5.349 0.634
CCA PI 1.667 ± 0.276 1.733 ± 0.259 1.742 ± 0.298 0.625
CCA RI 0.785 ±0.062 0.800 ± 0.057 0.801  ± 0.059 0.581
ICA VPS, cm/s 91.142 ± 18.944 86.886 ± 19.331 97.443 ± 23.819 0.160
ICA VED, cm/s 29.972 ± 8.601 27.806 ± 5.878 28.572 ± 5.410 0.565
ICA PI 1.228 ± 0.176 1.223 ± 0.370 1.323 ± 0.173 0.507
ICA RI 0.672 ± 0.053 0.656 ± 0.1495 0.700 ± 0.050 0.485
ECA VPS, cm/s 67.643 ± 15.530 68.085 ± 17.631 73.038 ± 11.666 0.392
ECA VED, cm/s 6.080 ± 1.994 7.297 ± 3.137 7.675 ± 4.812 0.419
ECA PI 2.302 ± 0.208 2.178 ± 0.393 2.256 ± 0.334 0.484
ECA RI 0.907 ± 0.032 0.881 ± 0.076 0.896 ± 0.058 0.406
FMD, % 10.792 ± 2.433 15.712 ± 4.476 10.689 ± 2.422 0.001 *
FMD absolute, 
mm 0.305 ± 0.072 0.436 ± 0.112 0.309 ± 0.077 0.002 *
parameters and FMD of the SCO group, during the 3 assessment 
phases.
    No statistically significant differences were observed in SBP, 
DBP, HR, axillary temperature and carotid parameters. However, 
axillary temperature showed a tendency to increase throughout the 
evaluations, reaching its highest value in LLP. Also, although not 
statistically significant, we verified the lowest VPS value of the CCA 
in the OP increasing in the LLP, similar behavior to the VPS of the 
ICA and ECA. The RI value of the ICA decreases from MF to OP, 
reaching the highest value in the LLP. 
    We observed statistically significant differences in the value of 
FMD throughout the menstrual cycle, in percentage and absolute 
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Table 5 Comparation of pressures, heart rate and temperature between groups.
Parameters MP (1º-4º day) p (SCO vs. CCO on MP) OP (12º-14º day)
p (SCO vs. CCO 
on OP)
LLP (26º-30º day)             
Pause OC(21º-28º day)
p (SCO vs. CCO on 
LLP/Pause OC)
SBP, mmHg
SCO 115.68 ± 7.95
0.748
114.061 ± 8.515
0.874
115.758 ± 8.908
0.125
CCO 114.47 ± 9.12 113.433 ± 9.402 110.00 ± 7.362
DBP, mmHg
SCO 69.21 ± 4.84
0.531
67.848 ± 6.145
0.967
68.333 ± 6.720
0.303
CCO 67.70 ± 6.02 67.733 ± 6.629 65.400 ± 5.887
HR, bpm
SCO 72.05 ± 10.30
0.758
72.545 ± 9.234
0.309
77.455 ± 10.153
0.425
CCO 72.80 ± 11.48 68.00 ± 5.716 74.100 ± 8.504
Temperature, °C
SCO 36.11 ± 0.61
0.751
36.182 ± 0.436
0.230
36.218 ± 0.765
0.253
CCO 36.16 ± 0.48 36.400 ± 0.362 36.520 ± 0.270
Table 6 Comparation of systolic and diastolic diameters of carotid arteries, between groups.
Parameters MP (1º-4º day) p (SCO vs. CCO on MP) OP (12º-14º day)
p (SCO vs. CCO 
on OP)
LLP (26º-30º day)             
Pause OC(21º-28º day)
p (SCO vs. CCO on 
LLP/Pause OC)
ACC VPS, cm/s
SCO 104.025 ± 20.184
0.900
101.045 ± 13.336
0.835
110.737 ± 15.224
0.475
CCO 102.910 ± 20.037 102.534 ± 18.702 105.618 ± 16.965
ACC VED, cm/s
SCO 21.820 ± 5.655
0.415
19.997 ± 5.370
0.899
21.420 ± 5.349
0.778
CCO 23.822 v 5.315 20.288 ± 4.936 21.980 ± 3.242
ACC PI
SCO 1.667 ± 0.276
0.405
1.733 ± 0.259
0.931
1.742 ± 0.298
0.506
CCO 1.576 ± 0.203 1.724 ± 0.238 1.672 ± 0.136
ACC RI
SCO 0.785 ± 0.062
0.460
0.800 ± 0.057
0.954
0.801  ± 0.059
0.586
CCO 0.765 ± 0.053 0.799 ± 0.052 0.790 ± 0.030
ACI VPS, cm/s
SCO 91.142 ± 18.944
0.914
86.886 ± 19.331
0.701
97.443 ± 23.819
0.889
CCO 90.199 ± 20.373 89.930 ± 16.041 96.196 ± 15.210
ACI VED, cm/s
SCO 29.972 ± 8.601
0.635
27.806 ± 5.878
0.172
28.572 ± 5.410
0.630
CCO 28.304 ± 7.07 24.531 ± 4.514 27.484 ± 4.693
ACI PI
SCO 1.228 ± 0.176
0.734
1.223 ± 0.370
0.226
1.323 ± 0.173
0.631
CCO 1.268 ± 0.331 1.403 ± 0.278 1.362 ± 0.190
ACI RI
SCO 0.672 ± 0.053
0.891
0.656 ± 0.1495
0.243
0.700 ± 0.050
0.654
CCO 0.677 ± 0.096 0.719 ± 0.074 0.711 ± 0.054
ACE VPS, cm/s
SCO 67.643 ± 15.530
0.262
68.085 ± 17.631
0.818
73.038 ± 11.666
0.132
CCO 74.197 ± 9.321 66.518 ± 12.467 63.076 ± 17.065
ACE VED, cm/s
SCO 6.080 ± 1.994
0.340
7.297 ± 3.137
0.120
7.675 ± 4.812
0.248
CCO 9.374 ± 10.994 5.032 ± 3.237 5.553 ± 3.060
ACE PI
SCO 2.302 ± 0.208
0.728
2.178 ± 0.393
0.169
2.256 ± 0.334
0.798
CCO 2.236 ± 0.582 2.414 ± 0.361 2.296 ± 0.371
ACE RI
SCO 0.907 ± 0.032
0.515
0.881 ± 0.076
0.176
0.896 ± 0.058
0.804
CCO 0.880 ± 0.128 0.921 ± 0.051 0.902 ± 0.055
Table 7 Comparation of carotid parameters between groups.
Parameters MP (1º-4º day) p (SCO vs. CCO on MP) OP (12º-14º day)
p (SCO vs. CCO 
on OP)
LLP (26º-30º day)             
Pause OC(21º-28º day)
p (SCO vs. CCO on 
LLP/Pause OC)
ACC DD, mm
SCO 5.264 ± 0.330
0.639
5.127 ± 0.427
0.880
5.218 ± 0.343
0.908
CCO 5.264 ± 0.469 5.100 ± 0.389 5.200 ± 0.371
ACC SD, mm
SCO 6.082 ± 0.334
0.398
5.909 ± 0.558
0.729
6.045 ± 0.356
0.350
CCO 5.920 ± 0.514 5.830 ± 0.464 5.880 ± 0.434
ACI DD, mm
SCO 4.427 ± 0.249
0.618
4.482 ± 0.417
0.840
4.391 ± 0.324
0.639
CCO 4.560 ± 0.829 4.530 ± 0.648 4.300 ± 0.535
ACI SD, mm
SCO 4.727 ± 0.329 
0.633
4.800 ± 0.471
0.776
4.709 ± 0.404
0.900
CCO 4.870 ± 0.914 4.880 ± 0.776 4.740 ± 0.687
ACE DD, mm
SCO 3.618 ± 0.555
0.724
3.509 ± 0.547
0.233
3.636 ± 0.639
0.079
CCO 3.530 ± 0.574 3.240 ± 0.443 3.170 ± 0.492
ACE SD, mm
SCO 3.900 ± 0.598
0.854
3.827 ± 0.604
0.155
3.864 ± 0.679
0.149
CCO 3.850 ± 0.633 3.470 ± 0.490 3.470 ± 0.495
risky to evolve into a possible relationship. Krejza et al[18] (2001) 
affirmed that when exposed to high concentrations of E2 leads to 
variations in the flow velocity of the carotid arteries.
    FMD is a noninvasive technique that provides information on 
endothelial function, a marker of vascular health[26]. As already 
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value (p = 0.001 and p = 0.002, respectively). There was an increase 
in their value from MP to OP (p = 0.023), decreasing later to near 
baseline in LLP (p = 0.012). 
    In the CCO group, the mean values ± SD along the menstrual 
cycle of the parameters also analyzed in the SCO group and already 
mentioned above are shown in Table 4 (Apendix). No statistically 
significant differences were observed in any of the variables. 
Comparative analysis between the SCO group and the CCO 
group
Table 5 shows the average values ± SD of SBP, DBP, HR and axillary 
temperature for both groups, as well as the significance value of the 
difference between them at each moment. There were no relevant 
variations in these parameters throughout the evaluations.
    Table 6 shows the systolic and diastolic diameters of the carotid 
arteries for both groups and the significance value of the difference 
between them at each moment. There were no significant changes in 
the diameters during the 3 evaluations.
DISCUSSION AND CONCLUSION
No studies were found in the literature that simultaneously evaluated 
the carotid arteries and FMD. However, many articles that study the 
two strands individually were found. In the present study, the right 
brachial artery was used in order to evaluate the vasodilatation after 
a period of hyperemia of the distal limb - FMD. When using carotid 
ultrasound, we tried to evaluate the carotid flow and, indirectly, 
the cerebral flow. The standardization of the various moments of 
evaluation was based on specific phases of the endocrine / hormonal 
behavior of the woman throughout her monthly cycle. Thus, in the 
SCO group, the first evaluation should be performed on the days 
when the hormone levels are lower, corresponding to the MP from 
the 1st to the 4th day, the second sample should be on the days when 
the levels of E2 are the highest, corresponding to OP from day 12 to 
day 16 and the third assessment on days when E2 levels were low 
again, on the LLP from the 26th to the 30th day. For the CCO group, 
the first sample was collected at the time of the start of contraception 
from day 1 to day 4 in order to evaluate its initial effect, the second 
evaluation on the days when ovulation was supposed to occur, from 
the 12th to the 16th day and the last collection on the days of the OC 
pause, from the 21st to the 28th day.
    All evaluations started with the measurement of BP and axillary 
temperature. An influence of E2 on BP is reported in women who 
do not use OC. Adkison et al[14] (2010) demonstrated that SBP and 
DBP decreased approximately 4 mmHg in LLP for 10 to 14 days 
in eumenorrheic women who did not use OC. Although we may 
consider this reduction in BP to be substantial, it has been estimated 
that a reduction of SBP by only 3 mmHg can lead to a reduction 
in cardiac mortality by 5-9% and stroke by 8-14%[27]. In our study, 
no significant variations were found in relation to BP in the SCO 
group, possibly due to the young age of the participants and to 
the fact that none of the participants included had high BP values. 
This may also justify the fact that the CCO group does not present 
significant changes in BP, although its elevation is described in young 
women using OC because of the presence of EE that exacerbates 
hepatic angiotensinogen production and, based on the renin system 
-angiotensin-aldosterone, causes an increase of BP[19]. The fact that 
young women are still relatively recent users of OC may be another 
argument in favor, so it is foreseeable that the increase in years 
of contraception will make their effects more evident. Regarding 
axillary temperature, it shows, though not significantly, a tendency 
to increase throughout the evaluations, reaching its highest value in 
LLP, possibly running as an argument in favor of the occurrence of 
ovulation.
     When we analyzed the variables obtained by the carotid 
ultrasound study, we did not find statistically significant changes 
in each group individually and in the comparison between groups. 
This behavior may be justified by the young age group and the 
reduced moments of evaluation. Possibly with a more advanced age 
section and with more collections throughout the cycle, statistically 
significant values could be reached. However, we found some trends 
that, although not statistically significant, could alert to possible 
fluctuations in agreement with the hormonal changes. In the SCO 
group, the ICA RI value decreases from MP to OP, increasing later to 
values above baseline. Krejza et al[23] (2003) when studying a group 
of healthy and non-users of OC during twelve days of the menstrual 
cycle, found a statistically significant decrease in the late follicular 
phase when compared to the basal values, raising the hypothesis of 
the RI variation of ICA due to E2 fluctuations. As RI is a measure of 
resistance of the distal vascular area to the insonation site, an increase 
in peripheral resistance will lead to a decrease in VED and an 
increase in VPS, according to mechanisms of reflection of pressure 
waves produced by distal arterioles and by cardiac compensating 
mechanisms, in order to compensate for the increase in resistance. 
It is known that there are numerous components that influence and 
change the impedance of a stable system and that can change VPS 
and VED and consequently RI, specifically cardiac output[23]. In 
our study, since there were no significant changes in HR and BP, 
we believe that there was no relevant change. Vascular compliance 
may also influence vascular impedance[23]. With the measurement 
of the systolic and diastolic diameters of the carotid arteries, in the 
present study, we verified that there were no significant variations 
throughout the menstrual cycle and, so it is possible to think that 
the cerebrovascular compliance remains without considerable 
modifications. Thus, we can think that the increase of the E2 
concentration with the late follicular phase and OP causes a decrease 
in the cerebral vascular impedance and in this way leads to a 
reduction of the RI. It is thought that the ER are present in endothelial 
cells and muscle cells of arteries and cerebral arterioles but not in 
the arteries carótidas[18,23]. The stimulation of these receptors by E2 
will increase the secretion of vasoactive substances such as NO, 
prostacyclin and prostaglandin, leading to a relaxation of the vascular 
musculature. Several investigators[18,23] also affirm the possibility of 
a distinct behavior when exogenous estrogen is present either in the 
form of OCP or in HRT. In our study, we evaluated young women 
using combined monophasic OCP, with a relative stabilization of RI 
throughout the menstrual cycle which in relation to the one presented 
previously, meets the expectations, since the contraceptive pill will 
keep circulating levels of E2 stable.
    Consciously, a “blind” comparison between carotid artery flow 
velocities and hormonal variations can be considered risky due to a 
set of factors related to both the lack of rigorous methodology and the 
lack of knowledge of the exact momentum of the menstrual cycle. 
This may explain why many researchers do not report differences 
in ICA flow velocity between the follicular and luteal phases of the 
cycle. However, several studies[28,29] have already demonstrated a 
variation of cerebral blood flow throughout the menstrual cycle but 
few are those that have studied in the carotid study and cerebral 
hemodynamics reason why its pathophysiological mechanisms 
are still not known. In fact, in our study, no statistically significant 
variations were found of VPS of CCA and ICA throughout the 
menstrual cycle, with only fluctuations occurring, admitting it is still 
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mentioned, vascular endothelial and smooth muscle cells have 
ER that upon their binding, increase the bioavailability of NO. 
Studies[23,28] demonstrated an increase in NO concentrations from 
the early follicular phase to the late follicular phase, returning to the 
basal levels in the luteal phase. In view of this, it is hypothesized that 
the increase of E2 production during the late / ovulatory follicular 
phase results in a greater opportunity for its binding to its receptors 
and thus increase the bioavailability of NO, a potent vasodilator and 
modulator of vascular reactivity[14]. Several investigators[14,30,31] when 
studying groups of healthy premenopausal young people with regular 
menstrual cycles and non-users of OC considered that an increase 
in vascular reactivity during the late/ovulatory follicular phase was 
a result of an increase in the bioavailability of NO secondary to a 
higher concentration of E2. Also in our study we obtained concordant 
results. In the SCO group, the FMD value increased significantly 
from MP to OP and later returned to basal values. In the CCO group, 
considerable stability was expected in the value of FMD, since OC 
prevents the occurrence of ovulation and the hormonal peak of E2. 
In fact, in our study we observed a relative stabilization of the FMD 
values and there wasn’t increase in vascular reactivity in OP, unlike 
the SCO group.
    As already mentioned, women at menopause achieve a CVDs risk 
similar to or greater than men. Although age, per se, has harmful 
effects on the vasculature, the reduction of E2 with menopause may 
add an aggravating factor of CVDs in postmenopausal women, 
making it difficult to distinguish the different contributions[32]. About 
70% of the beneficial effects of E2 focus on vasodilation, decreased 
homocysteine levels, decreased levels of fibrinogen and lipoprotein A 
and their positive effects on the development of atherosclerosis[33]. So, 
together with all the mechanisms triggered by the physiological aging 
of cells, there is a further development of cardiovascular disease.
    Based on these visible effects of E2, HRT seems to be a plausible 
solution for the reduction of vascular dysfunction potentiated by 
menopause. Although for many decades this therapy remained 
famous among women and the clinical community, it was largely 
challenged as of 2002, as a result of the publication of a study by the 
Women’s Health Initiative Research Group (WHI)[34], indicating that 
the long-term risks of HRT outweigh the benefits and that this risk 
varies as HRT is based on the use of estrogen alone or in combined 
use of it with progesterone. These risks include increased incidence 
of breast cancer, endometrial cancer, early onset coronary disease, 
pulmonary embolism and stroke. In the absence of a clear consensus, 
other studies have argued that there is no clear evidence of an 
increase in these risks trying to rest clinicians and patients regarding 
the use of this therapy and that it should always be considered or 
adapted to the clinical profile of the woman[35].
    In conclusion, our results are in agreement with the available 
studies that demonstrate the possible influence of E2 on arterial 
response and cerebral hemodynamics. It is likely that fluctuations of 
this hormone in the cerebral blood flow maybe change and/or serve 
as a pathophysiological or therapeutic basis for events such as stroke 
and some forms of epilepsy and migraine triggered by menstruation. 
These linking mechanisms are still not properly established, since 
the research in this area is scarce. Similarly, the improvement of 
arterial function in OP seems to be partly due to an increase in NO 
secondary to an increase in E2 concentration. These data highlight 
the importance of standardizing the timing of vascular testing in 
premenopausal women because the results may vary depending on 
the stage of the cycle it is in. Following this line of reflection, the 
phase of the “correct” menstrual cycle to assess cardiovascular risk 
in a premenopausal woman without hormonal interposition would be 
from the 1st to the 7th day of the menstrual cycle, already described 
in some guidelines[26]. Also in BP, the phase of the menstrual cycle 
should be taken into account in its measurement and interpretation in 
clinical context. 
Limitations of the study
Using the calendar method and standardizing the menstrual cycle 
as 28 days, according to the literature, the respective phases of the 
cycle were estimated which vary from woman to woman. However, 
accurate knowledge of the duration of each cycle, of each specific 
phase and of the exact time of ovulation is difficult without the use 
of specific control methods that were not possible to achieve. In 
addition, a daily assessment of the participant would be necessary 
to evaluate its evolution, which was impossible both due to lack of 
resources and schedule incompatibility. With this awareness and 
through a detailed selection of the young people and with the greatest 
possible rigor, the three assessment phases were marked. With the 
appropriate resources and a multi-center contribution, it would be 
interesting to evaluate this issue on a wider scale taking into account 
several physiological and non-physiological variables, accompanying 
women’s menstrual years.
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